Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V
subunit vaccine using SA-4-1BBL as a novel adjuvant.
One of the major advantages of recombinant
subunit vaccine is the product can be purified from the contaminants to a much higher degree and the production can be achieved at commercial level (Liljeqvist and Stahl, 1999; Jenkins, 2001; Clark and Cassidy-Hanley, 2005).
Epitope prediction and vaccine candidate characterization have been reported first time for Pakistani field isolate of AAV-4 and could eventually be proposed as an important component of immunodiagnostics and
subunit vaccine for future studies.
A number of vaccine approaches have been investigated including live attenuated viruses, inactivated viruses, chimeric vaccines, virus-like particles, DNA vaccines and
subunit vaccines all of which have their own specific advantages and disadvantages (Pulmanausahakul et al.
Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based
subunit vaccine.
Global vaccination program of children with inactivated killed whole cell bacteria significantly reduced disease related mortality, but reactogenecity of the initial whole cell vaccines (Wc) led to generation of acellular pertussis
subunit vaccines (Ac) composed of the main immunoprotective pertussis antigens, including Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), pertactin and fimberiae 2-3 antigens (3).
Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B
subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
Hawaii Biotech's dengue monovalent vaccine candidate is the first recombinant
subunit vaccine for dengue to enter clinical studies.
Shire's vaccine unit also has a Cdn$80 million agreement with Technology Partnerships Canada to develop a pipeline portfolio of protein-based or
subunit vaccines.
The Herpes Zoster
subunit vaccine (Shingrix) containing QS-21 Stimulon is recommended for herpes zoster and related complications for immunocompetent adults age 50 year and older; herpes zoster and related complication for immunocompetent adults who previously received Zoster Vaccine Live (Zostavax); as well as preferred over Zoster Vaccine Live (Zostavax) for herpes zoster and related complications.
THE HERPES ZOSTER
SUBUNIT vaccine was effective and safe for adults aged 70 and older in a phase III manufacturer-sponsored clinical trial, which was reported online in the New England Journal of Medicine.
